$IRTC

Turakhia Minang sold $884K of IRTC

Turakhia Minang (CHIEF MED/SCI OFCR EVP ADVTECH) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.

Original reporting
SEC EDGAR · Turakhia Minang
Published Aug 11, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings of an executive officer.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing alone does not provide a new fundamental driver.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on total holdings, prior sales cadence, tax events, or whether the sale was part of a broader planned schedule.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

Form 4 shows Turakhia Minang, iRhythm’s EVP AdvTech, sold 7,093 shares on 2026-08-10 for about $884,151 at $124.6512.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

The filing is primary-source and time-stamped, but insider sales are common and the article provides no accompanying operational or financial change.

Market effects

Minimal; insider sale does not change sector fundamentals or regulatory outlook based on the provided text.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management and does not necessarily signal reduced confidence, especially without any accompanying negative company-specific news.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Turakhia Minang

    Chief Med/SCI Officer, EVP AdvTech, reported the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.

$IRTCMed

Why iRhythm (IRTC) Shares Are Trading Lower Today

iRhythm Technologies (IRTC) shares fell about 2.8% after Truist cut its price target to $18 from $160, keeping a Buy rating. The move followed iRhythm’s strong Q2 results, including $224.2M revenue (+20.1% YoY) and EPS of $0.58, and a raised FY revenue guidance midpoint to $885M.

$IRTCHighAI 9/10

iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised

iRhythm Holdings (IRTC) reported Q2 2026 adjusted EPS of 58 cents versus an adjusted loss of 32 cents a year earlier, beating the Zacks Consensus Estimate by 5900%. Revenue rose 20.1% to $224.2 million. Gross margin increased to 72.8%. Full-year 2026 revenue guidance was raised to $880 million-$890 million and adjusted EBITDA margin to 13%-14%.

$IRTCMedAI 8/10

IRTC Q2 Deep Dive: Product Portfolio Expansion and Margin Gains Highlight Quarter

iRhythm Technologies (IRTC) reported Q2 revenue of $224.2M, above analysts’ $219.2M estimate, and adjusted EPS of $0.58. Adjusted EBITDA was $43.3M versus $26.13M estimates. The company slightly raised full-year revenue guidance to $885M. It also agreed to acquire VitalConnect to expand cardiac monitoring offerings and expects margin gains from automation.